Table 3.
Risk of a frequent exacerbator with the SNPs and haplotypes of OXSR1 in the non-smoker group
| Locus | Exacerbation | Genotype (N, %) | Codominant | Dominant | Recessive | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC | CR | RR | Total | OR | P | Pcorr | OR | P | Pcorr | OR | P | Pcorr | ||
| rs9839010 | Exa < 2 | 544 (61.7%) | 293 (33.3%) | 44 (5%) | 881 (100%) | 0.48 [0–0.86] | 0.013 | 0.131 | 0.41 [0.2–0.84] | 0.015 | 0.151 | 0.29 [0.06–1.47] | 0.136 | 1.000 |
| Exa ≥ 2 | 56 (75.7%) | 15 (20.3%) | 3 (4.1%) | 74 (100%) | ||||||||||
| rs61005484 | Exa < 2 | 778 (88.3%) | 101 (11.5%) | 2 (0.2%) | 881 (100%) | 0.86 [0.32–2.27] | 0.759 | 1.000 | 0.87 [0.32–2.33] | 0.779 | 1.000 | 0 [0–0] | 0.999 | 1.000 |
| Exa ≥ 2 | 67 (90.5%) | 7 (9.5%) | 0 (0%) | 74 (100%) | ||||||||||
| rs4955408 | Exa < 2 | 319 (36.3%) | 420 (47.7%) | 141 (16%) | 880 (100%) | 1.01 [0.65–1.59] | 0.957 | 1.000 | 1.12 [0.59–2.13] | 0.720 | 1.000 | 0.84 [0.34–2.05] | 0.702 | 1.000 |
| Exa ≥ 2 | 23 (31.1%) | 42 (56.8%) | 9 (12.2%) | 74 (100%) | ||||||||||
| rs1392283 | Exa < 2 | 693 (78.8%) | 175 (19.9%) | 12 (1.4%) | 880 (100%) | 0.53 [0.23–1.23] | 0.140 | 1.000 | 0.43 [0.17–1.1] | 0.078 | 0.784 | 2.03 [0.2–20.44] | 0.547 | 1.000 |
| Exa ≥ 2 | 65 (87.8%) | 8 (10.8%) | 1 (1.4%) | 74 (100%) | ||||||||||
| rs112221585 | Exa < 2 | 755 (86.1%) | 119 (13.6%) | 3 (0.3%) | 877 (100%) | 1.28 [0–2.81] | 0.541 | 1.000 | 1.32 [0.59–2.95] | 0.506 | 1.000 | 0 [0–0] | 0.999 | 1.000 |
| Exa ≥ 2 | 62 (83.8%) | 12 (16.2%) | 0 (0%) | 74 (100%) | ||||||||||
| rs74919163 | Exa < 2 | 450 (52.1%) | 351 (40.6%) | 63 (7.3%) | 864 (100%) | 1.22 [0–2.05] | 0.461 | 1.000 | 1.29 [0.7–2.37] | 0.422 | 1.000 | 1.09 [0.24–4.93] | 0.912 | 1.000 |
| Exa ≥ 2 | 31 (43.1%) | 38 (52.8%) | 3 (4.2%) | 72 (100%) | ||||||||||
| rs1384006 | Exa < 2 | 486 (55.2%) | 341 (38.7%) | 54 (6.1%) | 881 (100%) | 0.47 [0–0.83] | 0.009 | 0.094 | 0.36 [0.18–0.72] | 0.004 | 0.038 | 0.58 [0.15–2.26] | 0.435 | 1.000 |
| Exa ≥ 2 | 55 (74.3%) | 15 (20.3%) | 4 (5.4%) | 74 (100%) | ||||||||||
| rs156260 | Exa < 2 | 681 (77.3%) | 187 (21.2%) | 13 (1.5%) | 881 (100%) | 1.3 [0.69–2.43] | 0.413 | 1.000 | 1.51 [0.77–2.98] | 0.229 | 1.000 | 0 [0–0] | 0.999 | 1.000 |
| Exa ≥ 2 | 55 (74.3%) | 19 (25.7%) | 0 (0%) | 74 (100%) | ||||||||||
| rs9880223 | Exa < 2 | 778 (88.3%) | 101 (11.5%) | 2 (0.2%) | 881 (100%) | 0.86 [0.32–2.27] | 0.759 | 1.000 | 0.87 [0.32–2.33] | 0.779 | 1.000 | 0 [0–0] | 0.999 | 1.000 |
| Exa ≥ 2 | 67 (90.5%) | 7 (9.5%) | 0 (0%) | 74 (100%) | ||||||||||
| rs2298417 | Exa < 2 | 636 (72.3%) | 225 (25.6%) | 19 (2.2%) | 880 (100%) | 1.87 [1.13–3.09] | 0.015 | 0.155 | 1.96 [1.05–3.66] | 0.035 | 0.353 | 3.41 [0.97–12.01] | 0.056 | 0.560 |
| Exa ≥ 2 | 47 (63.5%) | 22 (29.7%) | 5 (6.8%) | 74 (100%) | ||||||||||
| rs2011 | Exa < 2 | 575 (65.3%) | 270 (30.6%) | 36 (4.1%) | 881 (100%) | 0.43 [0.22–0.84] | 0.013 | 0.131 | 0.38 [0.17–0.81] | 0.013 | 0.132 | 0.24 [0.03–2.05] | 0.192 | 1.000 |
| Exa ≥ 2 | 59 (79.7%) | 14 (18.9%) | 1 (1.4%) | 74 (100%) | ||||||||||
| Exa ≥ 2 | 0 (0%) | 9 (12.2%) | 65 (87.8%) | 74 (100%) | ||||||||||
| Block1_ht1 | Exa < 2 | 199 (22.6%) | 462 (52.4%) | 220 (25%) | 881 (100%) | 0.82 [0.53–1.28] | 0.390 | 1.000 | 0.69 [0.32–1.49] | 0.347 | 1.000 | 0.85 [0.43–1.72] | 0.660 | 1.000 |
| Exa ≥ 2 | 17 (23%) | 44 (59.5%) | 13 (17.6%) | 74 (100%) | ||||||||||
| Block1_ht2 | Exa < 2 | 101 (11.5%) | 396 (44.9%) | 384 (43.6%) | 881 (100%) | 0.95 [0.6–1.51] | 0.837 | 1.000 | 0.86 [0.46–1.58] | 0.620 | 1.000 | 1.21 [0.43–3.38] | 0.718 | 1.000 |
| Exa ≥ 2 | 7 (9.5%) | 39 (52.7%) | 28 (37.8%) | 74 (100%) | ||||||||||
| Exa ≥ 2 | 3 (4.1%) | 40 (54.1%) | 31 (41.9%) | 74 (100%) | ||||||||||
| Block2_ht2 | Exa < 2 | 32 (3.6%) | 285 (32.3%) | 564 (64%) | 881 (100%) | 1.34 [0.78–2.3] | 0.297 | 0.891 | 1.41 [0.75–2.66] | 0.289 | 0.867 | 1.42 [0.3–6.85] | 0.661 | 1.000 |
| Exa ≥ 2 | 2 (2.7%) | 24 (32.4%) | 48 (64.9%) | 74 (100%) | ||||||||||
CC common allele homozygote, CR heterozygote, RR minor allele homozygote, SE standard error of mean, Pcorr corrected P value for multiple comparisons
Pcorr corrected P values using the effective number of independent marker loci (MeffLi) calculated by SNPSpD for each SNP (MeffLi = 10.03501), and using the number of haplotypes (n = 3) for each haplotypes
*Adjusted for age, sex, serum total IgE level, predicted FEV1% at the first visit, and total ICS and systemic steroid dose in the 1st year of visit as covariates